Oppenheimer Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $11.00

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) had its price objective dropped by Oppenheimer from $13.00 to $11.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "market perform" rating on the stock. Oppenheimer's target price would indicate a potential downside of 41.76% from the company's current price.

DYN has been the topic of a number of other reports. Royal Bank Of Canada boosted their price target on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the stock an "outperform" rating in a research report on Thursday, November 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Lifesci Capital raised Dyne Therapeutics to a "strong-buy" rating in a research note on Tuesday, October 14th. Stifel Nicolaus cut their price objective on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Finally, HC Wainwright increased their target price on shares of Dyne Therapeutics from $38.00 to $46.00 and gave the stock a "buy" rating in a research note on Thursday, November 6th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $34.40.

Get Our Latest Research Report on DYN

Dyne Therapeutics Price Performance

NASDAQ DYN traded down $0.78 during trading hours on Wednesday, reaching $18.89. The company's stock had a trading volume of 370,417 shares, compared to its average volume of 2,640,617. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $35.68. The company's 50-day moving average is $15.88 and its two-hundred day moving average is $12.90. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -4.90 and a beta of 1.15.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.05. On average, equities analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the transaction, the chief executive officer owned 199,539 shares of the company's stock, valued at $2,675,817.99. This trade represents a 1.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 14.14% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Dyne Therapeutics by 27.6% in the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company's stock valued at $123,469,000 after purchasing an additional 2,109,257 shares during the last quarter. RA Capital Management L.P. boosted its holdings in shares of Dyne Therapeutics by 52.2% in the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company's stock valued at $101,613,000 after buying an additional 3,333,248 shares in the last quarter. Atlas Venture Life Science Advisors LLC raised its stake in Dyne Therapeutics by 13.9% during the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company's stock worth $95,505,000 after acquiring an additional 1,111,111 shares in the last quarter. TCG Crossover Management LLC boosted its stake in Dyne Therapeutics by 42.1% in the second quarter. TCG Crossover Management LLC now owns 3,766,660 shares of the company's stock valued at $35,859,000 after acquiring an additional 1,116,510 shares in the last quarter. Finally, Braidwell LP grew its holdings in shares of Dyne Therapeutics by 431.6% during the first quarter. Braidwell LP now owns 3,621,344 shares of the company's stock worth $37,879,000 after purchasing an additional 2,940,162 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Read More

• Five stocks we like better than Dyne Therapeutics
• 3 Must-Buy Warren Buffett Stocks for Volatile Times
• Guardian Pharmacy Stock Pops on Q3 Strength and Upbeat Forecast
• Most Volatile Stocks, What Investors Need to Know
• Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay
• Should You Add These Warren Buffett Stocks to Your Portfolio?
• Occidental Petroleum is a Buy in Q4 2025

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dyne Therapeutics Right Now?

Before you consider Dyne Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.

While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here